CHAPTER 3 74 REFERENCES 1. van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016;115(6):716-24. 2. Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger L, Snijders M, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154(1):124-30. 3. Reijnen C, Küsters-Vandevelde HVN, Ligtenberg MJL, Bulten J, Oosterwegel M, Snijders M, et al. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome. Int J Cancer. 2020;147(2):478-89. 4. van Weelden WJ, van der Putten LJM, Inda MA, van Brussel A, Snijders M, Schriever LMM, et al. Oestrogen receptor pathway activity is associated with outcome in endometrial cancer. Br J Cancer. 2020;123(5):785-92. 5. Reijnen CV, S.W.; Draak, R.; Sweegers, S.; Snijders, M.P.L.M.; Gestel van, P.; Eikelenboom, A.; Pijnenborg, J.M.A.;, Bulten, J.; Küsters-Vandevelde, H.V.N. Pure and mixed clear cell carcinoma of the endometrium: a molecular and immunohistochemical analysis study. 2022. 6. Eijkelenboom A, Kamping EJ, Kastner-van Raaij AW, Hendriks-Cornelissen SJ, Neveling K, Kuiper RP, et al. Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags. J Mol Diagn. 2016;18(6):851-63.
RkJQdWJsaXNoZXIy MTk4NDMw